### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### **SCHEDULE 13G**

### Under the Securities Exchange Act of 1934 (Amendment No. )\*

### **Emergent BioSolutions Inc.**

(Name of Issuer)

# Common Stock, \$0.001 par value per share

(Title of Class of Securities)

### 29089Q 10 5

(CUSIP Number)

#### November 14, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d - 1(b) o Rule 13d - 1(c) ⊠ Rule 13d - 1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

	CUSIP No. 29089Q 10 5		13G	Page 2 of 5 pages			
1	S.S OR I.R.S. I	NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON					
	Michigan Biol	ogic Products, Inc.					
2	CHECK THE	APPROPRIATE BOX	(a) x (b) o				
3	SEC USE ONI	SEC USE ONLY					
4		CITIZENSHIP OR PLACE OF ORGANIZATION Michigan, United States					
	NUMBER OF SHARES	5 SOI 0*	E VOTING POWER				
	BENEFICIALLY OWNED BY	6 SHA 0	ARED VOTING POWER				
	EACH	7 SOI 0	E DISPOSITIVE POWER				
	REPORTING PERSON	<b>8</b> SHA	ARED DISPOSITIVE POWER				
	WITH		4,849*				
9	AGGREGATE 1,934,849*	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,934,849*					
10	CHECK BOX	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF 7.0%**	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12		YPE OF REPORTING PERSON*					
	со						

\* Michigan Biologic Products, Inc. ("MBPI") is a party to a voting agreement, dated June 30, 2004, pursuant to which it granted a proxy to BioPharm, L.L.C. ("BioPharm") to vote all of the shares of Emergent BioSolutions Inc. (the "Issuer") that it owns in the same manner and to the same extent as BioPharm votes its own shares of the Issuer. MBPI is a party to another voting agreement, dated June 30, 2004, pursuant to which it granted a proxy to Fuad El-Hibri, the General Manager of Intervac, L.L.C. to vote all of the shares that it owns of the Issuer in the manner set forth in that voting agreement.

Therefore, as of the date of this filing, MBPI beneficially owns 1,934,849 shares of the Issuer over which it has shared dispositive power with Robert Calvin Myers, the President and majority shareholder of MBPI but no voting power.

\*\* Based on 27,596,249 shares of Emergent BioSolutions Inc. issued and outstanding as of December 31, 2006.

Item 1(a)	Name of Issuer:		
	Emergent BioSolutions Inc.		
Item 1(b)	Address of Issuer's Principal Executive Offices:		
	2273 Research Blvd. Suite 400 Gaithersburg, Maryland 20850		
Item 2(a)	Name of Person Filing:		
	Michigan Biologic Products, Inc.		
Item 2(b)	Address of Principal Business Office or, if None, Residence:		
	5723 Delta River Drive Lansing, MI 48906		
Item 2(c)	Citizenship/Place of Organization:		
	Michigan, United States		
Item 2(d)	Title of Class of Securities:		
	Common Stock, \$0.001 par value		
Item 2(e)	CUSIP Number:		
	29089Q 10 5		
Item 3	Not applicable.		
Item 4	Ownership.		
	(a) Amount Beneficially Owned: <b>1,934,849</b>		
	(b) Percent of Class: <b>7.0%</b>		
	(c) Number of shares as to which such person has:		
	(i) sole power to vote or to direct the vote: <b>0</b>		

	(ii) shared power to vote or to direct the vote: <b>Not applicable.</b>			
	(iii) sole power to dispose or to direct the disposition of: <b>Not applicable.</b>			
	(iv) shared power to dispose or to direct the disposition of: <b>1,934,849</b>			
Item 5	Ownership of Five Percent or Less of a Class:			
	If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.			
Item 6	Ownership of More than Five Percent on Behalf of Another Person:			
	Not applicable.			
Item 7	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.			
	Not applicable.			
Item 8	Identification and Classification of Members of the Group.			
	Not applicable.			
Item 9	Notice of Dissolution of Group.			
	Not applicable.			
Item 10	Certification.			
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.				

## **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2007

## Michigan Biologic Products, Inc.

By: /s/ Carl A. Valenstein Name: Carl A. Valenstein Title: Attorney-in-fact

\* Duly authorized under Power of Attorney appointing Carl A. Valenstein attorney-in-fact, dated November 8, 2006, by Robert C. Myers, President of Michigan Biologic Products, Inc., filed as Exhibit 24 to Michigan Biologic Product, Inc.'s Form 3 filed with the SEC on November 14, 2006, and incorporated by reference herein.